Postchemoradiotherapy Positron Emission Tomography Predicts Pathologic Response and Survival in Patients With Esophageal Cancer

被引:55
作者
Jayachandran, Priya [1 ]
Pai, Reetesh K. [2 ]
Quon, Andrew [3 ]
Graves, Edward [1 ]
Krakow, Trevor E. [1 ]
La, Trang [1 ]
Loo, Billy W., Jr. [1 ]
Koong, Albert C. [1 ]
Chang, Daniel T. [1 ]
机构
[1] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA
[3] Stanford Univ, Div Nucl Med, Stanford, CA 94305 USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2012年 / 84卷 / 02期
关键词
Esophageal cancer; Positron emission tomography; PET; Treatment response; METABOLIC TUMOR VOLUME; SQUAMOUS-CELL CARCINOMA; ESOPHAGOGASTRIC JUNCTION; FDG-PET; CHEMORADIOTHERAPY; CHEMORADIATION; SURGERY; ADENOCARCINOMAS; THERAPY; UTILITY;
D O I
10.1016/j.ijrobp.2011.12.029
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To correlate the prechemoradiotherapy (CRT) and post-CRT metabolic tumor volume (MTV) on positron emission tomography (PET) scanning with the pathologic response and survival in patients receiving preoperative CRT for esophageal cancer. Materials and Methods: The medical records of 37 patients with histologically confirmed Stage I-IVA esophageal cancer treated with CRT with or without surgical resection were reviewed. Of the 37 patients, 21 received preoperative CRT (57%) and 16 received definitive CRT (43%). All patients had a pre-CRT and 32 had a post-CRT PET scan. The MTV was measured on the pre-CRT PET and post-CRT PET scan, respectively, using a minimum standardized uptake value (SUV) threshold x, where x = 2, 2.5, 3, or the SUV maximum x 50%. The total glycolytic activity (TGA(x)) was defined as the mean SUV x MTVx. The MTV ratio was defined as the pre-CRT PET MTV/post-CRT MTV. The SUV ratio was defined similarly. A single pathologist scored the pathologic response using a tumor regression grade (TRG) scale. Results: The median follow-up was 1.5 years (range, 0.4-4.9). No significant correlation was found between any parameters on the pre-CRT PET scan and the TRG or overall survival (OS). Multiple post-CRT MTV values and post-TGA values correlated with the TRG and OS; however, the MTV2.5Post and TGA(2.5Post) had the greatest correlation. The MTV2 ratio correlated with OS. The maximum SUV on either the pre-CRT and post-CRT PET scans or the maximum SUV ratio did not correlate with the TRG or OS. Patients treated preoperatively had survival similar compared with those treated definitively with a good PET response (p = 0.97) and significantly better than that of patients treated definitively with a poor PET response (p < 0.0001). Conclusion: The maximum SUV was not a predictive or prognostic parameter. The MTV2.5 and TGA(2.5) were useful markers for predicting the response and survival on the post-CRT PET scan. The MTV2 ratio also correlated with survival. Post-CRT PET can potentially guide therapy after CRT. (C) 2012 Elsevier Inc.
引用
收藏
页码:471 / 477
页数:7
相关论文
共 27 条
[21]   Positron emission tomography and pathological evidence of response to neoadjuvant therapy in adenocarcinoma of the esophagus [J].
Smithers, B. M. ;
Couper, G. C. ;
Thomas, J. M. ;
Wong, D. ;
Gotley, D. C. ;
Martin, I. ;
Harvey, J. A. ;
Thomson, D. B. ;
Walpole, E. T. ;
Watts, N. ;
Burmeister, B. H. .
DISEASES OF THE ESOPHAGUS, 2008, 21 (02) :151-158
[22]   Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus [J].
Stahl, M ;
Stuschke, M ;
Lehmann, N ;
Meyer, HJ ;
Walz, MK ;
Seeber, S ;
Klump, B ;
Budach, W ;
Teichmann, R ;
Schmitt, M ;
Schmitt, G ;
Franke, C ;
Wilke, H .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) :2310-2317
[23]   2-fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma [J].
Swisher, SG ;
Erasmus, J ;
Maish, M ;
Correa, AM ;
Macapinlac, H ;
Ajani, JA ;
Cox, JD ;
Komaki, RR ;
Hong, D ;
Lee, HK ;
Putnam, JB ;
Rice, DC ;
Smythe, WR ;
Thai, L ;
Vaporciyan, AA ;
Walsh, GL ;
Wu, TT ;
Roth, JA .
CANCER, 2004, 101 (08) :1776-1785
[24]   Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781 [J].
Tepper, Joel ;
Krasna, Mark J. ;
Niedzwiecki, Donna ;
Hollis, Donna ;
Reed, Carolyn E. ;
Goldberg, Richard ;
Kiel, Krystyna ;
Willett, Christopher ;
Sugarbaker, David ;
Mayer, Robert .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (07) :1086-1092
[25]   From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors [J].
Wahl, Richard L. ;
Jacene, Heather ;
Kasamon, Yvette ;
Lodge, Martin A. .
JOURNAL OF NUCLEAR MEDICINE, 2009, 50 :122S-150S
[26]   Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging [J].
Weber, WA ;
Ott, K ;
Becker, K ;
Dittler, HJ ;
Helmberger, H ;
Avril, NE ;
Meisetschläger, G ;
Busch, R ;
Siewert, JR ;
Schwaiger, M ;
Fink, U .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (12) :3058-3065
[27]   Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction [J].
Wieder, Hinrich A. ;
Ott, Katja ;
Lordick, Florian ;
Becker, Karen ;
Stahl, Alexander ;
Herrmann, Ken ;
Fink, Ulrich ;
Siewert, Joerg Ruediger ;
Schwaiger, Markus ;
Weber, Wolfgang A. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2007, 34 (12) :1925-1932